Investing Profile

John McKearn

InvestorVC
Venture Capital / BioPharma R&D
Photo of John McKearn, Managing Director at RiverVest

Signal uses Gmail to reveal intro paths. Email content is never read.

Sign in with Google →
cb
RiverVest Managing Director
$100K - $10.0M
$1M
16
$184.4M
CompanyStageDateRound SizeTotal Raised
Wugen
Series CAug 2025$120M
Series BJul 2021$170M
$290M
Co-investors: Bali Muralidhar (Abingworth), Niall O’Donnell (RiverVest)
OncoResponse
Series DMay 2023$14M
$14M
Bonum Therapeutics
Series ANov 2022$93M
$93M
Co-investors: Karl Handelsman (Codon Capital)
Good Therapeutics
Series BDec 2021$8M
$8M
Allakos
Series BDec 2017$100M
Series ASep 2014$10M
Series AAug 2014$25M
$140M
Arch Oncology
Series AAug 2016$86M
$86M
Co-investors: Peter Moldt (Novo Ventures)
Otonomy
Series DApr 2014$49M
Series CSep 2013$46M
Series BAug 2010$39M
Series BAug 2010$39M
$170M
Co-investors: Chau Khuong (OrbiMed), Niall O’Donnell (RiverVest), Peter Bisgaard (Pivotal bioVenture Partners), Bill Harrington (Osage University Partners), Brian Dovey (Domain Associates), Heather Preston
ZS Pharma
Series DMar 2014$55M
Series COct 2012$46M
$100M